PROGRAM CHAIRS
Lucia M. Novak, MSN, ANP-BC, BC-ADM
President, Diabesity, LLC, North Bethesda, MD
Co-executive Director, Capital Health, and Metabolic Center
Capital Diabetes and Endocrine Associates
Silver Spring and Camp Springs, Maryland
Natalie J. Bellini, DNP, FNP-BC, BC-ADM, CDCES
Assistant Professor of Medicine
Case Western Reserve University
Program Director Diabetes Technology
Diabetes and Metabolic Care Center
University Hospitals
Cleveland, Ohio
PROGRAM OVERVIEW
This enduring program focuses on enhancing clinicians’ ability to screen and identify early-stage type 1 diabetes (T1D). In addition, the program will overview T1D screening criteria, follow-up after screening results, and communicating effectively with patients to guide timely treatment decisions. Learners will also explore evidence-based criteria for selecting appropriate candidates for T1D disease-modifying therapies, implementing protocols to ensure their safe and efficient administration, as well as how to appropriately refer to specialty care to enable their earlier use.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat, or see patients with, or at high risk for, T1D, including primary care clinicians, pediatricians, pediatric and adult endocrinologists, diabetes educators, nurses, infusion professionals, and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon the completion of this program, learners should be better able to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions
- Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.0 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Lucia M. Novak, MSN, ANP-BC, BC-ADM | Receives consulting fees from Ascencia & is on the speaker’s bureau for Abbott, Novo Nordisk, Sanofi, Nestle |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 17, 2025
EXPIRATION DATE: September 17, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
